Italia - italiano - Ministero della Salute

fatro s.p.a. - niclosamide, levamisolo cloridrato - niclosamide - 750 milligrammo (i); levamisolo cloridrato - nd, niclosamide - 1500 mg; levamisolo cloridrato - nd, levamisolo cloridrato - nd ; niclosamide - 750 mg, levamisolo cloridrato - nd ; niclosamide - 1500 mg - levamisole, combinations

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

bayer ag - niclosamide - niclosamide

Italia - italiano - Ministero della Salute

zoetis italia s.r.l. - pyrantel pamoato, niclosamide monoidrato - pyrantel pamoato - 230.6 milligrammo (i); niclosamide monoidrato - 675.2 milligrammo (i), pyrantel pamoato - 230.6 mg; niclosamide monoidrato - 675.2 mg - combinations of tetrahydropyrimidines

Unione Europea - italiano - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamide - epilessia, parziale - antiepilettici, - lacosamide ucb è indicato come monoterapia e in terapia aggiuntiva nel trattamento di parziale-inizio convulsioni con o senza secondaria generalizzazione in adulti, adolescenti e bambini a partire dai 4 anni di età con epilessia.

Unione Europea - italiano - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamide - epilessia - antiepilettici, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamide - epilessia - antiepilettici, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teva b.v. - lacosamide - lacosamide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - lacosamide - lacosamide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

g.l. pharma gmbh - lacosamide - lacosamide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

doc generici srl - lacosamide - lacosamide